Format

Send to

Choose Destination
Intern Med J. 2018 Oct;48(10):1269-1272. doi: 10.1111/imj.14058.

Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.

Petelin L1,2, James PA1,2,3, Trainer AH1,2,3.

Author information

1
Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
2
Parkville Familial Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
3
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

Abstract

Federal funding for germline genetic testing in hereditary breast and ovarian cancer (HBOC) was recently introduced. Germline testing for HBOC under Medicare Benefits Schedule items 73296/73297 can be requested by any specialist, whereas the previous state- and territory-funded testing was limited to those operating within a familial cancer service. The impact of this decentralisation of HBOC testing on health and economic outcomes is uncertain, primarily as it has potential to significantly disrupt the clinical framework that generated the evidence used to justify clinical implementation of the Medicare Benefits Schedules.

KEYWORDS:

familial cancer; germline testing; public health

PMID:
30288903
DOI:
10.1111/imj.14058
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center